Protara Therapeutics (TARA) News Today → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free TARA Stock Alerts $2.67 -0.04 (-1.48%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2, 2024 | americanbankingnews.comOpaleye Management Inc. Sells 9,230 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) StockJune 2, 2024 | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Increase in Short InterestJune 1, 2024 | insidertrades.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 9,230 SharesMay 31, 2024 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest UpdateProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,360,000 shares, a growth of 32.0% from the April 30th total of 1,030,000 shares. Based on an average daily volume of 381,100 shares, the days-to-cover ratio is currently 3.6 days.May 24, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 33,000 Shares of StockMay 23, 2024 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 33,000 SharesProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) major shareholder Opaleye Management Inc. sold 33,000 shares of the firm's stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $3.06, for a total value of $100,980.00. Following the transaction, the insider now directly owns 124,250 shares in the company, valued at approximately $380,205. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.May 21, 2024 | globenewswire.comProtara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation SummitMay 18, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 70,885 Shares of StockMay 12, 2024 | investing.comOpaleye Management sells shares in Protara Therapeutics for $567kMay 11, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 30,600 Shares of StockMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002May 2, 2024 | investorplace.comTARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024May 2, 2024 | sfgate.comProtara Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateApril 17, 2024 | msn.comProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54April 15, 2024 | finance.yahoo.comProtara Therapeutics, Inc. (TARA)April 9, 2024 | markets.businessinsider.comBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC TreatmentApril 5, 2024 | msn.comProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via EquityApril 5, 2024 | markets.businessinsider.comProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline ChlorideApril 5, 2024 | markets.businessinsider.comProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock UpApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCMarch 23, 2024 | investorplace.com3 Stocks That Could Help You Retire on a Private IslandMarch 13, 2024 | markets.businessinsider.comBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market OpportunityMarch 13, 2024 | chron.comProtara Therapeutics: Q4 Earnings SnapshotMarch 13, 2024 | globenewswire.comProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 3, 2024 | finance.yahoo.comTARA Aug 2024 7.500 callMarch 3, 2024 | finance.yahoo.comTARA May 2024 2.500 putMarch 1, 2024 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short InterestProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 59,000 shares, a decrease of 33.0% from the January 31st total of 88,100 shares. Based on an average daily trading volume, of 71,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are short sold.February 28, 2024 | theglobeandmail.comNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024February 28, 2024 | globenewswire.comProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | msn.comNorthSea Therapeutics commences Phase IIa trial for IFALD therapyFebruary 17, 2024 | finance.yahoo.comWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateJanuary 25, 2024 | seekingalpha.comCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout OptionalityDecember 2, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)November 30, 2023 | finance.yahoo.comProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNovember 5, 2023 | benzinga.comProtara Therapeutics Stock (NASDAQ:TARA) Earnings Dates and Earning CallsNovember 5, 2023 | msn.comProtara Therapeutics reports Q3 resultsNovember 3, 2023 | msn.comProtara Therapeutics files for $300M mixed shelfNovember 3, 2023 | finance.yahoo.comProtara Therapeutics Inc (TARA) Announces Q3 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comProtara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateOctober 24, 2023 | msn.comProtara begins dosing in Phase II lymphatic malformation cell therapy trialOctober 23, 2023 | finance.yahoo.comProtara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsOctober 7, 2023 | benzinga.comNon Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)September 10, 2023 | finance.yahoo.comHere's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationSeptember 5, 2023 | finance.yahoo.comProtara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)August 4, 2023 | msn.comHC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy RecommendationAugust 3, 2023 | msn.comProtara Therapeutics (TARA) Price Target Decreased by 6.96% to 32.03 Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW TARA Media Mentions By Week TARA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼0.840.77▲Average Medical News Sentiment TARA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼01▲TARA Articles Average Week Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CSBR News BCLI News CADL News IVVD News GLUE News SCLX News CHRS News ELEV News FENC News CGEN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored